Repligen (RGEN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Repligen (RGEN) is Neutral.

The composite score behind that read is +0.06, weighing +0.38 of bullish evidence against -0.22 bearish.

Repligen last closed at $173.88, +6.13% on the session.

Against the IVW growth benchmark the position is +5.33% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

2 graded predictions for RGEN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Repligen in the 2nd percentile on valuation and the 42nd percentile on return on equity, where 100 is best.

Repligen is classified under Health Care / Life Sciences Tools & Services, with a market capitalisation of $10.40B.

StockMap tracks Repligen as the 16th largest of the 41 companies it covers in the Life Sciences Tools & Services industry, part of the Health Care sector.

Across that group the current two-week reads are 37 Neutral, 2 Moderate Outperform and 2 Moderate Underperform.

On that composite Repligen ranks 25th of 41 in the group, against a group median of +0.06.